VCYT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VCYT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Veracyte's PE Ratio without NRI is 71.27. Veracyte's 5-Year EBITDA growth rate is -6.00%. Therefore, Veracyte's PEG Ratio for today is N/A.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Veracyte's PEG Ratio or its related term are showing as below:
During the past 13 years, Veracyte's highest PEG Ratio was 14.69. The lowest was 9.08. And the median was 12.35.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
The historical data trend for Veracyte's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veracyte Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
PEG Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Veracyte Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
PEG Ratio | Get a 7-Day Free Trial | - | - | - | 9.14 | - |
For the Diagnostics & Research subindustry, Veracyte's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Veracyte's PEG Ratio falls into.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.
Veracyte's PEG Ratio for today is calculated as
PEG Ratio | = | PE Ratio without NRI | / | 5-Year EBITDA Growth Rate* |
= | 71.268057784912 | / | -6.00 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Veracyte (NAS:VCYT) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Thank you for viewing the detailed overview of Veracyte's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
John Leite | officer: Chief Commercial Officer-CLIA | 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Rebecca Chambers | officer: Chief Financial Officer | 3052 ORCHARD DR., SAN JOSE CA 95134 |
Jonathan Wygant | officer: VP, Chief Accounting Officer | 3750 TORREY VIEW COURT, SAN DIEGO X1 92130 |
Karin Eastham | director | C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037 |
Robert S Epstein | director | |
Evan/ Fa Jones | director | C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878 |
Jens Holstein | director | C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Muna Bhanji | director | C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Phillip G. Febbo | officer: Chief Scientific & Med Officer | C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
John L Bishop | director | |
Bonnie H Anderson | director, officer: President & CEO | 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Giulia C Kennedy | officer: Chief Scientific & Med Officer | 338 MAIN STREET #26E, SAN FRANCISCO CA 94105 |
Eliav Barr | director | C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Marc Stapley | officer: Chief Executive Officer | 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121 |
Kevin K Gordon | director | 155 S LIMERICK RD, LIMERICK PA 19468 |
From GuruFocus
By GuruFocus News • 11-07-2024
By GuruFocus Research • 09-27-2024
By Business Wire • 12-05-2024
By GuruFocus News • 10-11-2024
By GuruFocus News • 11-05-2024
By GuruFocus News • 12-06-2024
By Business Wire • 10-30-2024
By GuruFocus News • 11-22-2024
By Business Wire • 10-02-2024
By GuruFocus Research • 10-01-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.